论文部分内容阅读
6月12日,中国首例制药企业状告最高主管机构一案,以卫生部败诉暂时告一段落。由此引起的“民告官”现象在国内逐渐明朗,同时也暴露出中国药品采购招标机制的漏洞及招标监督亟待完善。
On June 12, China’s first pharmaceutical company sued the supreme competent authority for the case and the defeat of the Ministry of Health came to an end temporarily. The resulting “Civil Complaint Officials” phenomenon gradually became clear in the country, but also exposed the loopholes in China’s bidding mechanism for pharmaceutical procurement and the urgent need for improvement of bidding supervision.